CalciMedica

The post CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference appeared first on CalciMedica.

CalciMedica's Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (

The post CalciMedica Announces One-for-Five Reverse Stock Split appeared first on CalciMedica.

Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program

The post CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates appeared first on CalciMedica.

--CalciMedica, Inc., a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results for the s

The post CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints appeared first on CalciMedica.

The post CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program appeared first on CalciMedica.

The post CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data appeared first on CalciMedica.

The post CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program appeared first on CalciMedica.